CN101742907A - 采用分泌型磷脂酶a2（spla2）抑制剂和spla2抑制剂组合疗法治疗心血管疾病和血脂异常 - Google Patents

采用分泌型磷脂酶a2（spla2）抑制剂和spla2抑制剂组合疗法治疗心血管疾病和血脂异常 Download PDF

Info

Publication number
CN101742907A
CN101742907A CN200880023061A CN200880023061A CN101742907A CN 101742907 A CN101742907 A CN 101742907A CN 200880023061 A CN200880023061 A CN 200880023061A CN 200880023061 A CN200880023061 A CN 200880023061A CN 101742907 A CN101742907 A CN 101742907A
Authority
CN
China
Prior art keywords
inhibitors
group
spla2
cvd
spla2 inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880023061A
Other languages
English (en)
Chinese (zh)
Inventor
若阿金·特里亚斯
科林·希斯洛普
保罗·特鲁科斯
伯娜丁·法拉斯
德布拉·奥丁克
斯科特·查德威克
肯尼思·古尔德
帕特里克·伊丘
玛丽安·莫肖尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anthera Pharmaceuticals Inc
Original Assignee
Anthera Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthera Pharmaceuticals Inc filed Critical Anthera Pharmaceuticals Inc
Publication of CN101742907A publication Critical patent/CN101742907A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200880023061A 2007-05-03 2008-05-02 采用分泌型磷脂酶a2（spla2）抑制剂和spla2抑制剂组合疗法治疗心血管疾病和血脂异常 Pending CN101742907A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US91591007P 2007-05-03 2007-05-03
US60/915,910 2007-05-03
US96959107P 2007-08-31 2007-08-31
US60/969,591 2007-08-31
US87486907A 2007-10-18 2007-10-18
US11/874,869 2007-10-18
PCT/US2008/062577 WO2008137803A1 (en) 2007-05-03 2008-05-02 Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies

Publications (1)

Publication Number Publication Date
CN101742907A true CN101742907A (zh) 2010-06-16

Family

ID=39943969

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880023061A Pending CN101742907A (zh) 2007-05-03 2008-05-02 采用分泌型磷脂酶a2（spla2）抑制剂和spla2抑制剂组合疗法治疗心血管疾病和血脂异常

Country Status (8)

Country Link
EP (1) EP2154958A4 (enExample)
JP (1) JP2010526152A (enExample)
CN (1) CN101742907A (enExample)
AU (1) AU2008247451A1 (enExample)
BR (1) BRPI0811486A2 (enExample)
CA (1) CA2686157A1 (enExample)
EA (1) EA200971020A1 (enExample)
WO (1) WO2008137803A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115040508A (zh) * 2022-07-28 2022-09-13 上海市同仁医院 吲哚-3-乙醛在制备新型抗肥胖活性制剂中的应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102271507A (zh) * 2009-01-08 2011-12-07 安塞拉制药有限公司 分泌型磷脂酶a2(spla2)抑制剂和烟酸药物组合物以及治疗心血管疾病和血脂异常的方法
RU2483707C1 (ru) * 2012-05-04 2013-06-10 Лира Талгатовна Гильмутдинова Способ санаторной терапии больных с метаболическим синдромом и артериальной гипертензией с применением сульфидных ванн

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1553814A (zh) * 2001-03-19 2004-12-08 ��Ұ����ҩ��ʽ���� 用于治疗动脉硬化的药物组合物
US20060094693A1 (en) * 2004-09-21 2006-05-04 Point Therapeutics, Inc. Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
ID27812A (id) * 1998-05-01 2001-04-26 Lilly Co Eli ESTER PENGHAMBAT sPLA2
AU2001236440A1 (en) * 2000-01-25 2001-08-07 Eli Lilly And Company Method for the treatment of inflammation with spla2 inhibitors
WO2002008189A1 (en) * 2000-07-24 2002-01-31 The University Of Queensland Compounds and inhibitors of phospholipases
EP1960356A2 (en) * 2005-11-03 2008-08-27 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1553814A (zh) * 2001-03-19 2004-12-08 ��Ұ����ҩ��ʽ���� 用于治疗动脉硬化的药物组合物
US20060094693A1 (en) * 2004-09-21 2006-05-04 Point Therapeutics, Inc. Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M-E PARADIS ET AL: "Visceral adipose tissue accumulation, secretory phospholipase A2-ⅡA and atherogenecity of LDL", 《INTERNATIONAL JOURNAL OF OBESITY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115040508A (zh) * 2022-07-28 2022-09-13 上海市同仁医院 吲哚-3-乙醛在制备新型抗肥胖活性制剂中的应用

Also Published As

Publication number Publication date
CA2686157A1 (en) 2008-11-13
AU2008247451A1 (en) 2008-11-13
EA200971020A1 (ru) 2010-10-29
EP2154958A1 (en) 2010-02-24
BRPI0811486A2 (pt) 2014-09-30
JP2010526152A (ja) 2010-07-29
EP2154958A4 (en) 2011-05-04
WO2008137803A1 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
JPH09505809A (ja) ヒドロキシカルバゾール化合物類による平滑筋移動および増殖の阻害
US20090062369A1 (en) Use of secretory phospholipase a2 (spla2) inhibitors to decrease spla2 levels
EP2827849A1 (en) Treatment of pulmonary hypertension with leukotriene inhibitors
JP2023057082A (ja) ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法
CN105473144A (zh) 用于加速斑块消退的组合物和治疗方法
US8048880B2 (en) Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
TW202342050A (zh) 用於治療進行性纖維化間質性肺病之新穎治療組合
WO2007083119A2 (en) Methods
US20100204249A1 (en) Secretory phospholipase a2 (spla2) inhibitor and niacin drug compositions and methods for treating cardiovascular disease and dyslipidemia
TW200306853A (en) Therapeutic agent for glomerular disease
AU2008247451A1 (en) Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
KR20210093900A (ko) 젬카빈, 이의 약학적으로 허용가능한 염, 이의 조성물 및 이의 사용 방법
US20100160361A1 (en) Treatment of major adverse cardiac events and acute coronary syndrome using secretory phospholipase a2 (spla2) inhibitor or spla2 inhibitor combination therapies
KR20100109840A (ko) 분비성 포스포리파제 ａ2 (ｓｐｌａ2) 억제제를 사용한 심혈관 질환 및 이상지혈증의 치료 및 ｓｐｌａ2 억제제 조합 요법
US20110269786A1 (en) Treatment of major adverse cardiac events and acute coronary syndrome in diabetic patients using secretory phospholipase a2 (spla2) inhibitor or spla2 inhibitor combination therapies
KR20230035601A (ko) 트롬복산 수용체 길항제 제제
AU2016222441A1 (en) Compound preparation of lercanidipine and atorvastatin
US20110301202A1 (en) Spla2 inhibitor conjugate compounds and methods of use
CN101534825A (zh) 含有贝特类药物的制剂及其制备方法
TW200406197A (en) Therapelitic agent for inflammatory bowel disease containing hydroxamic acid as effective component
Kuryata et al. MS385 CORONARY CIRCULATION AND LEFT VENTRICULAR FUNCTION: EFFECT OF REVASCULARIZATION IN PATIENTS WITH PRESERVED LEFT VENTRICLE SYSTOLIC FUNCTION

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100616